The role of selection in the risk of bleeding with dabigatran in patients with atrial fibrillation

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1243-1244

  Klil Drori, Adi ^a,b   Azoulay, Laurent ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; CARDIAC PATIENT; HUMAN; LETTER; OUTPATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FEMALE; MALE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 84937509645     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1277     Document Type: Letter

References (5)

1. Hernandez I, Baik SH, Pi?era A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18-24.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
3. Graham DJ, Reichman ME,WerneckeM, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157.
4. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-249.
5. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-2696.